ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$119.46
+0.43%Price chart
Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.1x
Market Cap
$10.42B
MomentumView details →
1D Return
+0.43%
YTD Return
−13.19%
RSI (14)
47.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.1x
Market Cap
$10.42B
RSI (14)
47.7
MomentumView details →
1D Return
+0.43%
YTD Return
−13.19%
SummaryUpdated Dec 1, 2025
ABIVAX SA (NASDAQ:ABVX) is a French biotechnology company founded in 2013 and headquartered in Paris. The company went public on the NASDAQ in October 2023, making it a relatively new entrant to the U.S. public markets. ABIVAX focuses on discovering and developing innovative drugs for treating inflammatory diseases, infectious diseases, and cancer. As a clinical-stage biopharmaceutical company, ABIVAX is currently advancing multiple drug candidates through various phases of clinical trials, with its lead compound ABX464 showing promise in treating autoimmune and inflammatory conditions.
Similar companies
Latest newsMore news →
Abivax raised $920 million in a capital raise to fund operations into Q4 2029.55d agoAbivax raised $920 million in a funding round to finance a solo U.S. launch of its bowel disease drug.62d agoAbivax SA requested a temporary halt of trading of its ordinary shares on Euronext Paris, effective from market opening at 9:00 a.m. on July 1, 2026.71d ago